FY2025 Earnings Estimate for Qiagen Issued By Zacks Research

Qiagen N.V. (NYSE:QGEN) – Analysts at Zacks Research cut their FY2025 earnings per share (EPS) estimates for Qiagen in a research note issued on Thursday, January 22nd. Zacks Research analyst Team now forecasts that the company will post earnings of $2.38 per share for the year, down from their prior forecast of $2.47. The consensus estimate for Qiagen’s current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen’s Q2 2026 earnings at $0.66 EPS, FY2026 earnings at $2.57 EPS, Q4 2027 earnings at $0.74 EPS and FY2027 earnings at $2.85 EPS.

Qiagen (NYSE:QGEN) last released its earnings results on Thursday, November 6th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.03. The firm had revenue of $532.58 million for the quarter, compared to analyst estimates of $525.68 million. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.60 earnings per share.

A number of other brokerages have also recently issued reports on QGEN. UBS Group restated a “neutral” rating on shares of Qiagen in a report on Wednesday. Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 29th. Barclays reissued an “overweight” rating and issued a $57.89 price target (up previously from $55.79) on shares of Qiagen in a report on Monday, December 15th. Citigroup downgraded Qiagen from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $57.89 to $52.63 in a research note on Thursday, December 11th. Finally, Deutsche Bank Aktiengesellschaft cut Qiagen from a “buy” rating to a “hold” rating and boosted their target price for the company from $52.00 to $54.00 in a research note on Thursday. Two equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $53.04.

Qiagen Stock Performance

Shares of QGEN stock opened at $55.56 on Monday. The stock has a market cap of $11.73 billion, a PE ratio of 28.68, a price-to-earnings-growth ratio of 2.67 and a beta of 0.66. The stock has a 50-day moving average of $48.88 and a 200-day moving average of $49.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.60 and a quick ratio of 2.30. Qiagen has a one year low of $39.61 and a one year high of $57.81.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in Qiagen during the third quarter worth $1,032,000. Generali Asset Management SPA SGR grew its position in shares of Qiagen by 102.8% in the 3rd quarter. Generali Asset Management SPA SGR now owns 68,880 shares of the company’s stock valued at $3,078,000 after acquiring an additional 34,912 shares during the period. Gateway Investment Advisers LLC acquired a new position in shares of Qiagen during the 3rd quarter worth about $1,197,000. Allspring Global Investments Holdings LLC increased its stake in shares of Qiagen by 5.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,874,356 shares of the company’s stock worth $133,140,000 after purchasing an additional 141,393 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Qiagen by 117.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,252,948 shares of the company’s stock valued at $60,217,000 after purchasing an additional 675,498 shares during the period. 70.00% of the stock is currently owned by institutional investors.

Trending Headlines about Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Zacks Research nudged its Q1 2027 EPS estimate up to $0.68 from $0.67, a small positive signal for near‑term earnings expectations that may be helping support the stock.
• Neutral Sentiment: Media pieces note that analysts are “conflicted” on Qiagen, highlighting mixed buy/hold/sell views rather than a consensus directional change; this increases focus and trading but doesn’t force a clear fundamental shift. Analysts Have Conflicting Sentiments on These Healthcare Companies
• Neutral Sentiment: A similar roundup notes mixed analyst views again (adds visibility and trading interest but not a unified directional signal). Analysts Conflicted on These Healthcare Names
• Negative Sentiment: Zacks Research lowered multiple quarterly EPS estimates (including Q3 2027 and Q4 2026) and trimmed near‑term forecasts overall — a signal that analysts see some softening in near‑term profit trends. Consensus full‑year EPS remains around $2.26, but the downward quarterly revisions are a near‑term negative for sentiment.
• Negative Sentiment: Deutsche Bank downgraded Qiagen, a direct negative from a major sell‑side firm that can pressure sentiment and weighing on shares despite the mixed analyst picture. Deutsche Bank downgrades Qiagen NV (QGEN)

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.